Study Groups and Drug Administration: If participant is found to be eligible to take part in this study, they will be randomly assigned (as in the flip of a coin) to 1 of 2 study groups. This is done because no one knows if one study group is better, the same, or worse than the other group. There is an equal chance of being in either group.
- Group 1 will receive ibrutinib alone.
- Group 2 will receive ibrutinib plus rituximab.
Study Drug Administration: Each cycle is 28 days. If participant is in Group 1, they will take 3 capsules of ibrutinib by mouth 1 time every day with 1 cup (8 ounces) of water. If participant is in Group 2, they will take 3 capsules of ibrutinib by mouth 1 time every day with 1 cup of water. Participant's doctor will tell them if they will start taking the ibrutinib on Day 1 or Day 2 of Cycle 1. Participant will receive rituximab by vein over between 3 and 8 hours on Days 1, 8, 15, and 22 of Cycle 1, then on Day 1 of Cycles 2-6. Participant will be given a diary to record when they take the ibrutinib. If participant misses a dose of ibrutinib, it can be taken as soon as possible on the same day with a return to the normal schedule the following day. Participant should not take extra capsules to make up the missed dose. Study Visits: On Days 8, 15, and 22 of Cycle 1:
- Participant will have a physical exam.
- Blood (about 1-2 teaspoons) will be drawn for routine tests.
After Cycles 1-6, then Cycles 9, 12, 15, 18, 21, and 24:
- Participant will have a physical exam.
- Blood (about 1-2 teaspoons) will be drawn for routine tests.
After Cycle 3 or 6, you will have a CT scan, MRI, or PET scan of the chest, abdomen, and pelvis to check the status of the disease. After Cycles 12 and 24, then every 12 cycles if the doctor thinks it is needed:
- Participant will have a bone marrow aspiration to check the status of the disease.
- Participant will have a CT scan, MRI, or PET scan of the chest, abdomen, and pelvis to check the status of the disease.
Once every 6 months after Cycle 24:
- Participant will have a physical exam.
- Blood (about 1-2 teaspoons) will be drawn for routine tests.
Length of Study: Participant may continue taking ibrutinib for as long as the doctor thinks it is in their best interest. Participant will no longer be able to take the study drug if the disease gets worse, if intolerable side effects occur, or if they are unable to follow study directions. Participant's participation on the study will be over after the follow-up visits. Follow-Up: At 60 days after the last dose of study drug(s), then about every 4 months for 5 years (or until the disease gets worse or a new treatment is started), blood (about 1-2 teaspoons) will be drawn for routine tests. This is an investigational study. Ibrutinib is not FDA approved or commercially available. It is currently being used for research purposes only. Rituximab is FDA approved and commercially available for the treatment of CLL. The combination of rituximab and ibrutinib is investigational. Up to 208 participants will be enrolled in this study. All will be enrolled at MD Anderson. |